Clinical Benefit of First-Line Cemiplimab in Patients with Locally Advanced NSCLC: Subgroup Analysis from EMPOWER-Lung 1

Bondarenko I., Sezer A., KILIÇKAP S., GÜMÜŞ M., Ozguroglu M., Gogishvili M., ...Daha Fazla

JOURNAL OF THORACIC ONCOLOGY, cilt.16, sa.10, 2021 (SCI-Expanded, Scopus) identifier

  • Yayın Türü: Makale / Özet
  • Cilt numarası: 16 Sayı: 10
  • Basım Tarihi: 2021
  • Dergi Adı: JOURNAL OF THORACIC ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Anahtar Kelimeler: Randomised Controlled Trials, Phase II and III Clinical Trials, Immune checkpoint inhibitors
  • İstanbul Üniversitesi-Cerrahpaşa Adresli: Hayır